The biggest difference is Retatrutide's unique side effect: dysesthesia (tingling sensations) in 20.9% of patients, not seen with either Semaglutide or Tirzepatide
GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia
Is retatrutide better than Ozempic
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors a novel mechanism not shared by currently licensed UK weight management medicines
Tirzepatide is given subcutaneously once a week and was examined in four worldwide phase III randomized, placebo-controlled clinical trials as part of the SURMOUNT Program, which also includes lifestyle modification
Pinyapat Chaipurihiran, Mousai Wellness Center References Dai H, Li Y, Lee YA, et al